Baicalein protects against type 2 diabetes via promoting islet β -cell function in Obese Diabetic Mice

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Fu, Yu ^a   Luo, Jing ^a   Jia, Zhenquan ^b   Zhen, Wei ^a   Zhou, Kequan ^c   Gilbert, Elizabeth ^a   Liu, Dongmin ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAICALEIN; INSULIN; TRIACYLGLYCEROL;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; APOPTOSIS; ARTICLE; BODY COMPOSITION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; FOOD INTAKE; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MALE; MIDDLE AGED; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SCUTELLARIA BAICALENSIS; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 84931001185     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/846742     Document Type: Article

References (60)

1. ADA, "Total Prevalence of Diabetes & Pre-diabetes," 2012.
2. H. King, R. E. Aubert, and W. H. Herman, "Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections," Diabetes Care, vol. 21, no. 9, pp. 1414-1431, 1998.
3. S. Golbidi, S. A. Ebadi, and I. Laher, "Antioxidants in the treatment of diabetes," Current Diabetes Reviews, vol. 7, no. 2, pp. 106-125, 2011.
4. M. Knip and H. Siljander, "Autoimmune mechanisms in type 1 diabetes," Autoimmunity Reviews, vol. 7, no. 7,pp. 550-557, 2008.
5. D. A. Stoffers, "The development of beta-cell mass: recent progress and potential role of GLP-1," Hormone and Metabolic Research, vol. 36, no. 11-12, pp. 811-821, 2004.
6. A. M. Hennige, D. J. Burks, U. Ozcan et al., "Upregulation of insulin receptor substrate-2 in pancreatic cells prevents diabetes," The Journal of Clinical Investigation, vol. 112, no. 10, pp. 1521-1532, 2003.
7. A. J. Scheen, "Diabetesmellitus in the elderly: insulin resistance and/or impaired insulin secretion?" Diabetes and Metabolism, vol. 31, no. 2, pp. S27-S34, 2005.
8. M. Stumvoll, B. J. Goldstein, and T. W. Van Haeften, "Type 2 diabetes: principles of pathogenesis and therapy," The Lancet, vol. 365, no. 9467, pp. 1333-1346, 2005.
9. M. Bruno, F. Piozzi, and S. Rosselli, "Natural and hemisynthetic neoclerodane diterpenoids from Scutellaria and their antifeedant activity," Natural Product Reports, vol. 19, no. 3, pp. 357-378, 2002.
10. Z. Hu, X. Yang, P. C. L. Ho et al., "Herb-drug interactions: a literature review," Drugs, vol. 65, no. 9, pp. 1239-1282, 2005.
11. X. Shang, X. He, M. Li et al., "The genus Scutellaria an ethnopharmacological and phytochemical review," Journal of Ethnopharmacology, vol. 128, no. 2, pp. 279-313, 2010.
12. K. Ishimaru, K. Nishikawa, T. Omoto, I. Asai, K. Yoshihira, and K. Shimomura, "Two flavone 2-glucosides fromScutellaria baicalensis," Phytochemistry, vol. 40, no. 1, pp. 279-281, 1995.
13. M. Li-Weber, "New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin," Cancer Treatment Reviews, vol. 35, no. 1, pp. 57-68, 2009.
14. V. Y.Waisundara, A. Hsu, B. K. Tan, and D. Huang, "Baicalin reduces mitochondrial damage in streptozotocin-induced diabetic Wistar rats," Diabetes/Metabolism Research and Reviews, vol. 25, no. 7, pp. 671-677, 2009.
15. H. X. Guo, D. H. Liu, Y. Ma et al., "Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet," Acta Pharmacologica Sinica, vol. 30, no. 11, pp. 1505-1512, 2009.
16. P. Pu, X. Wang, M. Salim et al., "Baicalein, a natural product, selectively activating AMPK2 and ameliorates metabolic disorder in diet-induced mice,"Molecular and Cellular Endocrinology, vol. 362, no. 1-2, pp. 128-138, 2012.
17. M. A. Yorek, "Treatment of diabetic neuropathy with baicalein: intervention atmultiple sites," ExperimentalNeurology, vol. 232, no. 2, pp. 105-109, 2011.
18. M. Himeji, T. Ohtsuki, H. Fukazawa et al., "Difference of growth-inhibitory effect of Scutellaria baicalensis-producing flavonoid wogonin among human cancer cells and normal diploid cell," Cancer Letters, vol. 245, no. 1-2, pp. 269-274, 2007.
19. S. Ikemoto, K. Sugimura, N. Yoshida et al., "Antitumor effects of Scutellariae radix and its components baicalein, baicalin, and wogonin on bladder cancer cell lines," Urology, vol. 55, no. 6, pp. 951-955, 2000.
20. Y. Huang, S. Tsang, X. Yao, and Z. Chen, "Biological properties of baicalein in cardiovascular system," Current Drug Targets: Cardiovascular and Haematological Disorders, vol. 5, no. 2, pp. 177-184, 2005.
21. L. Yang, H. Sun, L. Wu et al., "Baicalein reduces inflammatory process in a rodent model of diabetic retinopathy," Investigative Ophthalmology and Visual Science, vol. 50, no. 5, pp. 2319-2327, 2009.
22. D. L. Evers, C. Chao, X. Wang, Z. Zhang, S. Huong, and E. Huang, "Human cytomegalovirus-inhibitory flavonoids: studies on antiviral activity and mechanism of action," Antiviral Research, vol. 68, no. 3, pp. 124-134, 2005.
23. Z. Bach-Olszewska, B. Jatczak, A. Rak et al., "Production of cytokines and stimulation of resistance to viral infection in human leukocytes by Scutellaria baicalensis flavones," Journal of Interferon and Cytokine Research, vol. 28, no. 9, pp. 571-581, 2008.
24. X. Yang, W. He,W. Lu, and F. Zeng, "Effects of scutellarin on liver function after brain ischemia/reperfusion in rats," Acta Pharmacologica Sinica, vol. 24, no. 11, pp. 1118-1174, 2003.
25. N. Lu, Y. Zhang, and Z. Gao, "Nitrite-glucose-glucose oxidase system directly induces rat heart homogenate oxidation and tyrosine nitration: effects of some flavonoids," Toxicology in Vitro, vol. 23, no. 4, pp. 627-633, 2009.
26. Y. Zhao,H. Li, Z. Gao, Y.Gong, and H. Xu, "Effects of flavonoids extracted from Scutellaria baicalensis Georgi on hemin-nitrite-H2O2 induced liver injury," European Journal of Pharmacology, vol. 536, no. 1-2, pp. 192-199, 2006.
27. Z. Fu, W. Zhang, W. Zhen et al., "Genistein induces pancreatic -cell proliferation through activation of multiple signaling pathways and prevents insulin-deficient diabetes in mice," Endocrinology, vol. 151, no. 7, pp. 3026-3037, 2010.
28. D. Liu,W.Zhen, Z. Yang, J.D.Carter, H. Si, andK. A. Reynolds, "Genistein acutely stimulates insulin secretion in pancreatic -cells through a cAMP-dependent protein kinase pathway," Diabetes, vol. 55, no. 4, pp. 1043-1050, 2006.
29. S. J. Brand, S. Tagerud, P. Lambert et al., "Pharmacological treatment of chronic diabetes by stimulating pancreatic -cell regeneration with systemic co-Administration of EGF and gastrin," Pharmacology and Toxicology, vol. 91, no. 6, pp. 414-420, 2002.
30. E. R. Gilbert, Z. Fu, and D. Liu, "Development of a nongeneticmouse model of type 2 diabetes," Experimental Diabetes Research, vol. 2011, Article ID 416254, 12 pages, 2011.
31. Z. Yang, M. Chen, L. B. Fialkow, J. D. Ellett, R. Wu, and J. L. Nadler, "The novel anti-inflammatory compound, lisofylline, prevents diabetes in multiple low-dose streptozotocin-treated mice.," Pancreas, vol. 26, no. 4, pp. e99-e104, 2003.
32. E. Larger, "Weight gain and insulin treatment," Diabetes and Metabolism, vol. 31, no. 4, part 2, pp. 4S51-4S56, 2005.
33. W. J. Schnedl, S. Ferber, J. H. Johnson, andC. B.Newgard, "STZ transport and cytotoxicity: specific enhancement in GLUT2-expressing cells," Diabetes, vol. 43, no. 11, pp. 1326-1333, 1994.
34. C. Tourrel, D. Bailbe,M. Lacorne, M.Meile, M. Kergoat, and B. Portha, "Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the -cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4," Diabetes, vol. 51, no. 5, pp. 1443-1452, 2002.
35. H. Sakuraba, H. Mizukami, N. Yagihashi, R. Wada, C. Hanyu, and S. Yagihashi, "Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients," Diabetologia, vol. 45, no. 1, pp. 85-96, 2002.
36. P. Marchetti, S. Del Guerra, L. Marselli et al., "Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin," Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 11, pp. 5535-5541, 2004.
37. I. Cozar-Castellano, N. Fiaschi-Taesch, T. A. Bigatel et al., "Molecular control of cell cycle progression in the pancreatic -cell," Endocrine Reviews, vol. 27, no. 4, pp. 356-370, 2006.
38. A. E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R. A. Rizza, and P. C. Butler, "-cell deficit and increased -cell apoptosis in humans with type 2 diabetes," Diabetes, vol. 52, no. 1, pp. 102-110, 2003.
39. S. Sreenan,A. J. Pick, M. Levisetti, A. C. Baldwin,W. Pugh, and K. S. Polonsky, "Increased -cell proliferationand reducedmass before diabetes onset in the nonobese diabeticmouse," Diabetes, vol. 48, no. 5, pp. 989-996, 1999.
40. W. L. Suarez-Pinzon, Y. Yan, R. Power, S. J. Brand, andA. Rabinovitch, "Combination therapy with epidermal growth factor and gastrin increases -cell mass and reverses hyperglycemia in diabetic NOD mice," Diabetes, vol. 54, no. 9, pp. 2596-2601, 2005.
41. Q. Wang and P. Brubaker, "Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice," Diabetologia, vol. 45, no. 9, pp. 1263-1273, 2002.
42. B. Rolin,M.O. Larsen, C. F. Gotfredsen et al., "The long-Acting GLP-1 derivative NN2211 ameliorates glycemia and increases -cell mass in diabetic mice,"The American Journal of Physiology: Endocrinology and Metabolism, vol. 283, no. 4, pp. E745-E752, 2002.
43. R. Basu, V. Chandramouli, B. Dicke, B. Landau, and R. Rizza, "Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis," Diabetes, vol. 54, no. 7, pp. 1942-1948, 2005.
44. R. A. Rizza, "Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy," Diabetes, vol. 59, no. 11, pp. 2697-2707, 2010.
45. M. E. Waltner-Law, X. L. Wang, B. K. Law, R. K. Hall, M. Nawano, and D. K. Granner, "Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production," Journal of Biological Chemistry, vol. 277, no. 38, pp. 34933-34940, 2002.
46. Q. F. Collins, H. Liu, J. Pi, Z. Liu, M. J. Quon, and W. Cao, "Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5-AMP-Activated protein kinase,"The Journal of Biological Chemistry, vol. 282, no. 41, pp. 30143-30149, 2007.
47. M.S.Choi,U. J. Jung, J.Yeo,M. J.Kim, andM. K. Lee, "Genistein and daidzein prevent diabetes onset by elevating insulin level and altering hepatic gluconeogenic and lipogenic enzyme activities in non-obese diabetic (NOD) mice," Diabetes/Metabolism Research and Reviews, vol. 24, no. 1, pp. 74-81, 2008.
48. S. Ae Park, M. Choi, S. Cho et al., "Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in C57BL/KsJ-db/db mice," Life Sciences, vol. 79,no. 12,pp. 1207-1213, 2006.
49. L. Zhang, G. Lin, B. Kovács, M. Jani, P. Krajcsi, and Z. Zuo, "Mechanistic study on the intestinal absorption and disposition of baicalein," European Journal of Pharmaceutical Sciences, vol. 31, no. 3-4, pp. 221-231, 2007.
50. L. Taiming and J. Xuehua, "Investigation of the absorption mechanisms of baicalin and baicalein in rats," Journal of Pharmaceutical Sciences, vol. 95, no. 6, pp. 1326-1333, 2006.
51. J. Xing, X. Chen, and D. Zhong, "Absorption and enterohepatic circulation of baicalin in rats," Life Sciences, vol. 78, no. 2, pp. 140-146, 2005.
52. J. Xing, X. Chen, Y. Sun, Y. Luan, and D. Zhong, "Interaction of baicalin and baicalein with antibiotics in the gastrointestinal tract," Journal of Pharmacy and Pharmacology, vol. 57, no. 6, pp. 743-750, 2005.
53. X.Han, S.Chen, Y. Sun, J. L.Nadler, andD. Bleich, "Induction of cyclooxygenase-2 gene in pancreatic -cells by 12-lipoxygenase pathway product 12-hydroxyeicosatetraenoic acid," Molecular Endocrinology, vol. 16, no. 9, pp. 2145-2154, 2002.
54. C. S. Nunemaker, M. Chen, H. Pei et al., "12-Lipoxygenaseknockout mice are resistant to inflammatory effects of obesity induced by Western diet," American Journal of Physiology-Endocrinology andMetabolism, vol. 295, no. 5, pp. E1065-E1075, 2008.
55. D.Bleich, S. Chen,B.Zipser,D. Sun,C.D.Funk, andJ.L.Nadler, "Resistance to type 1 diabetes induction in 12-lipoxygenase knockout mice," Journal of Clinical Investigation, vol. 103, no. 10, pp. 1431-1436, 1999.
56. J. D. Deschamps, V. A. Kenyon, and T. R. Holman, "Baicalein is a potent in vitro inhibitor against both reticulocyte 15-human and platelet 12-human lipoxygenases," Bioorganic andMedicinal Chemistry, vol. 14, no. 12, pp. 4295-4301, 2006.
57. S. G. Straub and G.W. G. Sharp, "Glucose-stimulated signaling pathways in biphasic insulin secretion," Diabetes/Metabolism Research and Reviews, vol. 18, no. 6, pp. 451-463, 2002.
58. Y. Zhang and D. Liu, "Flavonol kaempferol improves chronic hyperglycemia-impaired pancreatic beta-cell viability and insulin secretory function," European Journal of Pharmacology, vol. 670, no. 1, pp. 325-332, 2011.
59. N. Dachicourt, P. Serradas, M.-H. Giroix, M.-N. Gangnerau, and B. Portha, "Decreased glucose-induced cAMP and insulin release in islets of diabetic rats: reversal by IBMX, glucagon, GIP," American Journal of Physiology, vol. 271, no. 4, part 1, pp. E725-E732, 1996.
60. G. G. Yue, T. W. Yip, Y. Huang, and W. Ko, "Cellular mechanism for potentiation of Ca2+-mediated Cl? secretion by the flavonoid baicalein in intestinal epithelia," Journal of Biological Chemistry, vol. 279, no. 38, pp. 39310-39316, 2004.